Europe Approves AbbVie's Skyrizi For Second Indication
Benzinga via Yahoo Finance· 8 months agoThe European Commission (EC) has approved AbbVie Inc's (NYSE: ABBV) Skyrizi (risankizumab) 150 mg...
Assertio (ASRT) to Report Q1 Earnings: What's in the Cards?
Zacks via Yahoo Finance· 2 months agoPrice and EPS Surprise Assertio Holdings, Inc. price-eps-surprise | Assertio Holdings, Inc. Quote In...
AbbVie's (ABBV) Skyrizi Gets Nod for Psoriatic Arthritis in EU
Zacks via Yahoo Finance· 8 months agoABBV announced that the European Commission (EC) approved its drug Skyrizi (risankizumab) for a...
5 Reasons to Invest in Horizon Therapeutics Amid Coronavirus
Zacks via Yahoo Finance· 2 years agoGood Rank and Rising Estimates: Horizon Therapeutics Public Limited Company HZNP carries a Zacks...
Does 2021's Best Biopharma to Work for Belong in Your Portfolio?
Motley Fool· 1 year agoConsider Horizon Therapeutics (NASDAQ: HZNP), which topped the magazine's best workplaces list for...
AbbVie Takes Another Step Toward Its Post-Humira Future
Motley Fool· 8 months agoSince AbbVie (NYSE: ABBV) began trading in December 2012, it has left the S&P 500 in the dust....
Medexus Reports Triamcinolone Hexacetonide Injectable Suspension Approved for Inclusion on...
GlobeNewswire via Yahoo Finance· 2 years agoMoreover, we believe our formulation has the potential to become the standard of care for the treatment of many severe joint diseases, as it significantly impacts the safety and cost-effectiveness ...